ZyVersa Therapeutics, Inc. (ZVSA) earnings
ZVSA earnings moved a median of -3.26% by the close. Quarterly and annual ZVSA reports and results, each read against the price at its own news timestamp. Back to the ZVSA overview →
18 measured ZVSA earnings events.
Where these ZVSA earnings landedvs 18 measured ZVSA earnings reactions
| Middle 50% of ZVSA earnings reactions | -5.89% to +0.87% |
|---|---|
| Median reaction (to close) | -3.26% |
| Measured reactions | 18 |
Point-in-time · zero look-ahead
Half of the 18 ZVSA earnings events with a measured close landed between -5.89% and +0.87%; 28% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q ZyVersa Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +3.80% | +1.17% | |
| ZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | +3.80% | +1.17% | |
| Form 10-K ZyVersa Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +0.00% | -6.98% | |
| Form 10-Q ZyVersa Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -1.26% | +3.70% | |
| ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results | Press release | -1.26% | +3.70% | |
| Form NT 10-Q ZyVersa Therapeutics, For: Sep 30 | SEC filing · Form NT | +0.00% | +8.68% | |
| Form 10-Q ZyVersa Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -6.25% | -6.13% | |
| ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones | Press release | -6.25% | -6.13% | |
| Form 10-Q ZyVersa Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +3.69% | +0.00% | |
| ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress | Press release | +3.69% | +0.00% | |
| Form 10-K ZyVersa Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -9.40% | -4.40% | |
| Form 10-Q ZyVersa Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -1.64% | -7.38% | |
| Form 10-Q ZyVersa Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -2.28% | -7.17% | |
| Form 10-K/A ZyVersa Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +2.50% | -5.18% | |
| Form 10-Q ZyVersa Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +2.50% | -5.18% | |
| Form 10-K ZyVersa Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -1.49% | -2.07% | |
| Form 10-Q ZyVersa Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +0.12% | -3.26% | |
| ZyVersa Therapeutics Reports Third Quarter 2023 Corporate Update and Financial Results | Press release | +0.12% | -3.26% |
Keep exploring
More ZVSA: analyst actions → · SEC filings → · ZVSA overview →